Search

everythinglearnresearchcommunity

for

Search:↓

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.

GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

The diphosphonate was the most effective at preventing calcification in rats.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

Enhanced stem cells can reduce fat buildup in eye tissue for Graves' disease.

GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.

GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.

GLP-1 agonists may help treat certain skin conditions.

Allopregnanolone increases growth and changes gene activity in human brain cancer cells.

Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.

GLP-1RAs may cause hair loss but could also help regrow hair in some cases.

Enhanced stem cells from the placenta can reduce fat buildup in eye tissue for Graves' disease.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

Newer GLP-1 drugs like semaglutide may cause hair loss.

Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.